Clinical Trial Update: A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer

View source ↗

Summary

A completed clinical trial studying the combination of fulvestrant and exemestane in postmenopausal women with advanced hormone receptor-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane)
• Faslodex (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Postmenopause, Breast Cancer | Status: COMPLETED